Elpiscience Announces CDE IND Clearance of ES014, a First in Class Anti-CD39xTGF-? Bispecific Antibody for Patients with Advanced Solid Tumors
SHANGHAI & SUZHOU, China & GERMANTOWN, Md.--(BUSINESS WIRE)--Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company…